Jeroen P Jansen

Summary

Affiliation: Mapi Values

Publications

  1. ncbi Network meta-analysis of survival data with fractional polynomials
    Jeroen P Jansen
    Mapi Values, Boston, USA
    BMC Med Res Methodol 11:61. 2011
  2. ncbi Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands
    J P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 21:1535-46. 2005
  3. ncbi Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1
    Jeroen P Jansen
    Mapi Values, Boston, MA, USA
    Value Health 14:417-28. 2011
  4. ncbi The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis
    Jeroen P Jansen
    Mapi Values, Boston, MA 02114, USA
    Semin Arthritis Rheum 40:275-84.e1-2. 2011
  5. ncbi Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
    Jeroen P Jansen
    Mapi Values, Boston, MA 02108, USA
    Value Health 12:234-44. 2009
  6. ncbi Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
    Jeroen P Jansen
    Mapi Values, 133 Portland Street, Boston, MA 02114, USA
    Ann Hematol 89:919-26. 2010
  7. ncbi Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis
    Jeroen P Jansen
    Mapi Values, 133 Portland Street, Boston, MA 02114, USA
    Pharmacoeconomics 28:323-44. 2010
  8. ncbi Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
    Jeroen P Jansen
    Mapi Values, Boston, Massachusetts 02114, USA
    Pharmacoeconomics 27:1045-56. 2009
  9. ncbi Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies
    Jeroen P Jansen
    Mapi Values, Boston, MA 02114, USA
    Curr Med Res Opin 25:1861-8. 2009
  10. ncbi Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 22:671-81. 2006

Collaborators

Detail Information

Publications32

  1. ncbi Network meta-analysis of survival data with fractional polynomials
    Jeroen P Jansen
    Mapi Values, Boston, USA
    BMC Med Res Methodol 11:61. 2011
    ..This assumption is implausible when hazard functions intersect, and can have a huge impact on decisions based on comparisons of expected survival, such as cost-effectiveness analysis...
  2. ncbi Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands
    J P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 21:1535-46. 2005
    ..To asses the cost-effectiveness of voriconazole in comparison to conventional amphotericin B and itraconazole for the treatment of invasive aspergillosis in the Netherlands...
  3. ncbi Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1
    Jeroen P Jansen
    Mapi Values, Boston, MA, USA
    Value Health 14:417-28. 2011
    ..We finish with a discussion of what to do if there are no direct or indirect treatment comparisons of randomized, controlled trials possible and a health-care decision still needs to be made...
  4. ncbi The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis
    Jeroen P Jansen
    Mapi Values, Boston, MA 02114, USA
    Semin Arthritis Rheum 40:275-84.e1-2. 2011
    ..To evaluate the efficacy of available bisphosphonate therapies regarding the prevention of vertebral, hip, and nonvertebral-nonhip fractures in postmenopausal women with osteoporosis...
  5. ncbi Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance
    Jeroen P Jansen
    Mapi Values, Boston, MA 02108, USA
    Value Health 12:234-44. 2009
    ..To evaluate the cost-effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of community-acquired complicated intraabdominal infections accounting for development of antibiotic resistance in the Dutch setting...
  6. ncbi Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
    Jeroen P Jansen
    Mapi Values, 133 Portland Street, Boston, MA 02114, USA
    Ann Hematol 89:919-26. 2010
    ..The cost-effectiveness of posaconazole depends on the IFI risk, which can vary by hospital...
  7. ncbi Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis
    Jeroen P Jansen
    Mapi Values, 133 Portland Street, Boston, MA 02114, USA
    Pharmacoeconomics 28:323-44. 2010
    ..This economic evaluation suggests that, from the UK NHS perspective, etoricoxib is the most cost-effective initial NSAID treatment for AS patients...
  8. ncbi Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK
    Jeroen P Jansen
    Mapi Values, Boston, Massachusetts 02114, USA
    Pharmacoeconomics 27:1045-56. 2009
    ....
  9. ncbi Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies
    Jeroen P Jansen
    Mapi Values, Boston, MA 02114, USA
    Curr Med Res Opin 25:1861-8. 2009
    ..The objective was to compare the efficacy of bisphosphonates regarding the prevention of vertebral fractures in postmenopausal women with osteoporosis...
  10. ncbi Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 22:671-81. 2006
    ..To evaluate the relative effectiveness of interventions with self-monitoring blood glucose and self-monitoring of urine glucose, versus interventions without self-monitoring, in terms of HbA(1c) reductions in type 2 diabetes mellitus...
  11. ncbi Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Value Health 9:12-23. 2006
    ..To assess the costs and cost-effectiveness of voriconazole in comparison to conventional amphotericin B (CAB) for the treatment of invasive aspergillosis in Germany...
  12. ncbi Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons
    Jeroen P Jansen
    Mapi Values Ltd, Boston, MA 02108, USA
    Value Health 11:956-64. 2008
    ..Next, the Bayesian MTC for continuous outcomes are presented. We finish with a discussion of how MTC can best be presented in order to maximize acceptance by target audiences, i.e., clinicians and market access decision-makers...
  13. ncbi Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 24:671-84. 2008
    ....
  14. ncbi Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK
    Jeroen P Jansen
    Mapi Values, Houten, The Netherlands
    Curr Med Res Opin 23:3069-78. 2007
    ..To evaluate the cost-effectiveness of etoricoxib, a cyclooxygenase (COX)-2 selective inhibitor, versus non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) in the treatment of ankylosing spondylitis (AS)...
  15. ncbi Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands
    Wiro B Stam
    Mapi Values, Houten, The Netherlands
    Eur J Haematol 81:467-74. 2008
    ..The present study evaluates the cost effectiveness of posaconazole vs. standard azoles for the prevention of IFIs in neutropenic patients in the Netherlands...
  16. ncbi Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Int J Chron Obstruct Pulmon Dis 7:415-20. 2012
    ....
  17. ncbi Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison
    Shannon Cope
    Mapi Consultancy, Boston, MA 02114, USA
    Value Health 15:524-33. 2012
    ..Indacaterol trial evidence was synthesized to provide coherent estimates of indacaterol 150 μg and indacaterol 300 μg relative to formoterol, salmeterol, and tiotropium...
  18. ncbi Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy
    Wiro B Stam
    Mapi Values, Houten, The Netherlands
    Value Health 11:830-41. 2008
    ..To evaluate the cost-effectiveness of caspofungin versus liposomal amphotericin B as empiric antifungal treatment in patients with neutropenic fever in Italy...
  19. ncbi Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden
    Shalini Naik
    Mapi Values, Boston, USA
    Scand J Infect Dis 43:504-14. 2011
    ..To evaluate the cost-effectiveness of caspofungin versus liposomal amphotericin B (L-AmB) for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden...
  20. ncbi A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK
    Karin Bruynesteyn
    Mapi Values, De Molen, Houten, The Netherlands
    Eur J Haematol 78:532-9. 2007
    ..To evaluate the cost-effectiveness of caspofungin vs. liposomal amphotericin B in the treatment of suspected fungal infections in the UK...
  21. ncbi Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck
    Anju Parthan
    Mapi Values, 133 Portland Street, Boston, Massachusetts 02114, USA
    Head Neck 31:1255-62. 2009
    ....
  22. ncbi Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
    Gert J D Bergman
    Mapi Values, Houten, The Netherlands
    Semin Arthritis Rheum 39:425-41. 2010
    ..To compare the patterns of American College of Rheumatology (ACR) response between tocilizumab and other biologic agents in patients with rheumatoid arthritis who have inadequate response to disease-modifying antirheumatic drugs (DMARD-IR)...
  23. ncbi Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    Value Health 16:403-17. 2013
    ..However, results may be sensitive to the assumed underlying survival function...
  24. ncbi Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis
    Shannon Cope
    Mapi Consultancy, Boston, MA, USA
    BMC Pulm Med 12:29. 2012
    ....
  25. ncbi Epidemiology of HIV-related neuropathy: a systematic literature review
    Sabyasachi Ghosh
    Mapi Values Boston, Massachusetts 02114, USA
    AIDS Res Hum Retroviruses 28:36-48. 2012
    ..However, it underscores the fact that complexity of the disease, along with absence of standardized diagnostic criteria, has considerably influenced the methodologies and outcomes of the studies...
  26. ncbi Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
    Jeroen P Jansen
    Mapi Consultancy, Boston, MA 02114, USA
    BMC Med Res Methodol 12:152. 2012
    ..However, bias is still present if there are systematic differences in treatment effect modifiers across comparisons...
  27. ncbi Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma
    Pascale Dequen
    Mapi Group, Houten, The Netherlands
    Oncologist 17:1376-85. 2012
    ..To compare the overall survival (OS) of patients treated with 3 mg/kg ipilimumab versus alternative systemic therapies in pretreated unresectable stage III or IV melanoma patients...
  28. ncbi Directed acyclic graphs can help understand bias in indirect and mixed treatment comparisons
    Jeroen P Jansen
    Mapi Group, Boston, MA 02114, USA
    J Clin Epidemiol 65:798-807. 2012
    ..To introduce and advocate directed acyclic graphs (DAGs) as a useful tool to understand when indirect and mixed treatment comparisons are invalid and guide strategies that limit bias...
  29. ncbi Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis
    Shannon Cope
    Mapi Values, Boston, MA, USA
    Int J Chron Obstruct Pulmon Dis 6:329-44. 2011
    ....
  30. ncbi Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison
    Maria Cecilia Vieira
    Mapi Values, Boston, MA, USA
    HIV Clin Trials 12:175-89. 2011
    ..Compare the efficacy of 2 NRTIs combined with raltegravir (RAL), efavirenz (EFV), or protease inhibitors (PI) in the management of antiretroviral-naïve HIV adult patients...
  31. ncbi An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer
    Debby C J Vissers
    Mapi Values, Houten, The Netherlands
    Value Health 14:274-81. 2011
    ..A decision-analysis model was developed to evaluate the cost-effectiveness of intranasal fentanyl spray (INFS) compared with oral transmucosal fentanyl citrate (OTFC) and fentanyl buccal tablet (FBT) for the treatment of BTCP...
  32. ncbi The relations between psychosocial factors at work and health status among workers in home care organizations
    Hege R Eriksen
    Department of Education and Public Health, University of Bergen and Unifob Health, Norway
    Int J Behav Med 13:183-92. 2006
    ..Higher psychological demands do not seem to be associated with severity of LBP, but does show an association with sick leave...